In plain English
AstraZeneca PLC develops and sells prescription medicines in oncology, rare disease and other therapeutic areas. The company is a…
Company stock · NASDAQ · US dollars
AZN
AstraZeneca PLC
$171.49
Today
−$1.08-0.63%
vs yesterday’s close
Live price
- Opened at
- $171.28
- Day high
- $171.75
- Day low
- $169.51
- Yesterday’s close
- $172.57
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Size
- Large company
- Market value
- $201.3 billion
- Number of shares
- 1.55 billion
- Country
- GB
- Went public
- Sep 21, 2007
- Exchange
- NASDAQ · US dollars
- Listing
- US listing on Nasdaq, priced in US dollars (AstraZeneca also trades in London).
- Website
- astrazeneca.com
Price chart Pro
Loading chart…
Loading chart…
Company briefing
What AZN is
Plain English context — why the name shows up in the news, and what to watch next.
Latest on this name
Insights & deeper context
11 recent cards — open any for the full deeper dive.
AstraZeneca/Amgen Drug Shows Significant Remission in Eosinophilic Esophagitis Study
In brief
Tezspire’s strong Phase 3 results could open a new revenue stream for AZN and AMGN in the EoE market.
Amgen, AstraZeneca Announces Data From Phase 3 CROSSING Study Demonstrated TEZSPIRE Showed Histologic Remission For 64.8% For 210 Mg Dose At Week 24; TEZSPIRE Also Reduced Frequency, Severity Of Dysphagia Symptoms 18.8 Points
In brief
TEZSPIRE shows strong efficacy in Phase 3, paving the way for approval and market entry.
AstraZeneca And Amgen's TEZSPIRE Met Co-Primary Endpoints In Phase III EoE Trial
In brief
TEZSPIRE shows durable, clinically meaningful remission and symptom relief in EoE, positioning it as a breakthrough therapy in a difficult-to-treat disease.
AstraZeneca to present overall survival data from four pivotal Phase III trials in Presidential Symposia at ESMO 2026 featuring Sone-Ve, IMFINZI® (durvalumab), TAGRISSO® (osimertinib) and savolitinib
In brief
AstraZeneca is poised to deliver breakthrough survival data across four key oncology trials at ESMO, potentially redefining treatment standards and boosting its pipeline profile.
insitro Announces a Strategic Collaboration with AstraZeneca for AI-enabled Discovery of Novel Therapeutics for MASH and Cardiomyopathies
In brief
Insitro and AstraZeneca are teaming up to use AI to hunt new drugs for MASH and heart disease, with Insitro getting $40 million upfront and up to $1.46 billion in future milestones.
Summit Therapeutics Soars Nearly 20% After AstraZeneca Bets $2 Billion on Cancer Drug Ivonescimab
In brief
AstraZeneca’s $2 billion stake in Summit could accelerate ivonescimab’s U.S. launch and boost Summit’s valuation, driving a near‑term rally in its stock.
Eccogene Receives $50 Million Milestone Payment from AstraZeneca Following Initiation of Global Phase 3 Program for Elecoglipron (AZD5004/ECC5004)
In brief
AstraZeneca’s $50 million milestone payment marks a key financial and developmental milestone for Eccogene’s elecoglipron program.
Astrazeneca Secures FDA Approval for New Breast Cancer Treatment
In brief
AZN secures a key breast‑cancer approval and delivers strong oncology and respiratory trial results, positioning it for growth in multiple therapeutic areas.
AstraZeneca, Amgen Score Phase 3 Win in Debilitating Swallowing Disease
In brief
Tezspire’s Phase 3 win positions it as the first approved treatment for EoE, potentially opening a sizable new market for AstraZeneca and Amgen.
AstraZeneca, Amgen Report Phase III Results For TEZSPIRE In Eosinophilic Esophagitis; TEZSPIRE Meets Key Endpoints In Phase III CROSSING Trial
In brief
TEZSPIRE’s Phase III trial shows sustained, clinically meaningful benefits in EoE, supporting its future development and market potential.
Cullinan Therapeutics Zipalertinib Combo Clears Key Phase 3 Hurdle As First-Line Lung Cancer Treatment Option Takes Shape
In brief
Cullinan Therapeutics' zipalertinib combo cleared a key Phase 3 hurdle, showing strong efficacy and tolerability in a first-line lung cancer treatment option.
Company reports
Official filings (US SEC and linked cards)
No filings here yet
Official report cards for AZN will show up here when available.
Broad market indexes (like the S&P 500, a basket of 500 large US companies) are shown through popular funds that track them (for example SPY). Company profile and prices use live market data when available.